Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on...

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and...

Streetwise Reports Examines Promising 'Hot' Alzheimer's Market for Biotech with 'Novel' Drug Candidate  SAN FRANCISCO, Nov. 23, 2017 (GLOBE NEWSWIRE) -- André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's...